Rimonabant is a selective cannabinoid CB1 receptor antagonist that has undergone extensive testing in the treatment of obesity in human subjects. The story of rimonabant as an anti-obesity compound begins with the understanding that the endocannabinoid system (cannabinoid receptors and their endogenous ligands) plays a significant role in stimulating appetite through both central and peripheral mechanisms (see Di Marzo and Matias, 2005 for review). The rimonabant in obesity (RIO) program consisted of four phase III clinical trials (RIO-Europe, RIO-Lipids, RIO-North America and RIO-Diabetes) that compared rimonabant (5–20 mg per day) with placebo and showed that rimonabant reduced bodyweight and improved cardiovascular and metabolic risk factors in both non-diabetic overweight or obese patients and in overweight and obese subjects with type II diabetes, inadequately controlled by metformin or sulphonylureas (Scheen et al., 2006 for RIO-Diabetes results; Gadde and Allison, 2006 for review).
Obesity predisposes individuals to an increased risk of developing many diseases, including atherosclerosis, diabetes and some immune-mediated disorders. Importantly, obesity is associated with chronic inflammatory responses, such as arthritis and Crohn’s disease (Mokdad et al., 2003; Mehrotra et al., 2004), which are characterized by abnormal cytokine production, increased synthesis of C-reactive protein and the activation of pro-inflammatory signalling pathways (Wellen and Hotamisligil, 2005). Many of these inflammatory mediators are produced through a complex network involving both immune and metabolic systems. In fact, adipose tissue is no longer considered to be an inert tissue, but it is emerging as an important factor in the regulation of many pathological processes. Various products of adipose tissue have been described and, among these, certain cytokines mainly produced by the adipocytes have been named adipocytokines, particularly adiponectin and leptin. Other products of adipocytes include tumor necrosis factor-
(TNF), interleukin-6, interleukin-1, mediators of the clotting process and certain complement factors (Wellen and Hotamisligil, 2005). The adipose tissue of obese individuals also contains a large number of macrophages, recruited by a chemokine released by adipocytes (CCL2), which are an additional source of cytokines (especially TNF) in the adipose tissue.
Adiponectin, exclusively produced by adipocytes, regulates the expression of many pro- and anti-inflammatory cytokines. Its main anti-inflammatory effect might be related to its capability to suppress the synthesis of TNF and interferon-
, and to induce the production of anti-inflammatory mediators such as interleukin-10. Consequently, many diseases have been associated with a reduced level of adiponectin, including inflammatory bowel disease and rheumatoid arthritis. The role of leptin in regulating inflammatory responses is incompletely understood even though there is an increased expression of leptin in conditions associated with the release of pro-inflammatory cytokines, particularly in animal models of experimental autoimmune encephalomyelitis, antigen-induced arthritis or experimentally induced colitis. Its role as pro-inflammatory molecule in addition to regulating neuroendocrine function, energy homeostasis, haematopoiesis and angiogenesis, has become increasingly evident and has been recently reviewed (La Cava and Matarese, 2004). Together, these findings suggest that there are important pathways that link metabolism with the immune system and vice versa.
Related articles
Buy acomplia online
acomplia sanofi
rimonabant news online
acomplia online
order rimonabant acomplia
About Acomplia Diet Pills - generic RimonabantAcomplia is all set to surprise the weight loss drug market. Acomplia has dual advantage attached to it property since it can help people both lose weight and quit smoking.
Acomplia (generic Rimonabant) works by blocking the CB-1 receptors that governs food intake and tobacco dependency. These receptors that are blocked by Acomplia are in the brain, and also throughout the body, notably in fat cells. Among other things, the CB-1 receptors blocked by Rimonabant account for the sudden surge of appetite felt by people who smoke marijuana. Doctors say that this system of receptors, CB-1, is disrupted by tobacco and by chronic overeating.
Acomplia restores the balance in the CB-1 receptors system, reducing dependence on tobacco and suppressing appetite. Since many smokers are also overweight, Rimonabant diet pills could end up doing double duty.
A new anti-obesity pill that has been shown to not only help lose weight and quit smoking could also be effective in helping people stop drug and alcohol addiction, scientists claim.
Acomplia, or rimonabant, is an experimental drug developed by the French pharmaceutical firm Sanofi-Aventis primarily as a diet pill, but the drug works differently that most diet pills in that it blocks the brain’s reward system.
It works by blocking the connection between a pleasure-seeking activity, like smoking or overeating, and the reward “feeling” it causes in the brain. The human body contains endocannabinoids, marijuana-like substances that can stimulate the brain’s reward system.
Acomplia blocks the effect of the natural endocannabinoids by keeping them from attaching to the brain cells they usually stimulate, scientists say.
In March of this year, Acomplia gained a great deal of attention when two research studies demonstrated that it could not only help people lose weight, but quit smoking
Losing weight is a dream comes true for overweight people. I too used to be fatty earlier, but everything changed when my doctor told me about Acomplia. That was a turning point of my life. Now, I too enjoy life to the fullest like others, thanks to Acomplia.
Acomplia is a weight loss drug that helps obese people in losing weight within a small span of time. Acomplia diet pills are also known as “magic pills”. It is difficult to control one’s appetite which is found to be one of the reasons behind weight gain. But this is what acomplia help you in by playing the role of appetite suppressant.
Different weight loss drug work differently. It is available in different colors in tablets as well as capsule form. Acomplia diet pills are available in strength of 20mg. In the market generic form of rimonabant is also available for weight loss.
Combine the intake of Acomplia diet pills with healthy nutritious diet and regular exercise to get the best results out of Acomplia diet pills. Just take few minutes out of your daily busy schedule to do some exercise and taking regular dose of Acomplia will work wonders for you, helping you in losing weight quickly.
Consult your doctor before taking Acomplia. Follow the prescription that he tells you otherwise you may have to face its adverse effect. In case you miss a dose, don’t panic, resume the dose as prescribed for the rest of the day, and never take an overdose as it may affect leave negative impacts.
Internet has opened up a new avenue. Now, you can buy acomplia online. More and more pharmacists are going online to give complete convenience to the buyer. Acomplia diet pills seeker now just needs to fill an online form and can get a faster access to their desired amount. Important feature of online pharmacies is that they offer you cheap acomplia diet pill saving your hard earned money. But to get the best one, you need to a bit of hardship. Collect catalogue of different suppliers of acomplia and choose the one that fits your need and budget to the best.
Weight loss may seem impossible to you. But, for quick weight loss acomplia diet pills will work as an effective alternative. Shop around and look for the dealer who can offer you cheap acomplia helping you lose those extra pounds of weight without spending much pounds out of your pocket.
One of the hot new diet pills in the news is Rimonabant Diet Pills. It was created to help people quit smoking and lose fat by blocking circuitry in the brain that gives the body cravings.
The diet pills, rimonabant accomplia is an appetite suppressant, but works by an entirely new approach by blocking the same primeval circuitry in the brain that gives pot-smokers the munchies. The French firm Sanofi-Synthelabo plans to seek U.S. approval to sell it under the brand “Accomplia” after more studies are finished next year. A study found that the pills helped people drop 20 pounds in a year, while the other concluded it increased smokers’ success at quitting, at least in the short-term. The drug will be marketed both for dieting and smoking cessation.
After a year, those who got the higher of two doses of Rimonabant had lost an average of 20 pounds and trimmed three inches from their waists. Nearly half of them took off 10 percent of their body weight. By comparison, those on placebos lost just five pounds. Those receiving accomplia improved in other ways, as well: their levels of good cholesterol rose 23 percent, while their triglycerides fell 15 percent.
In a recent study, 1,036 overweight or obese patients with blood lipid disorders were randomly placed in one of three groups (placebo vs. 5 mg or 20 mg per day of Rimonabant-Acomplia). After one year of treatment, patients receiving 20 mg per day of Rimonabant-Acomplia lost an average of 20 pounds, compared to only 5 pounds for patients on placebo. Further comparisons between the placebo and 20 mg per day Rimonabant-Acomplia group showed that the latter patients enjoyed significant improvements in waist circumference and HDL-C and triglyceride levels, all important factors in maintaining heart health. The drug was said to be well tolerated, with only mild and transient side effects like dizziness and gastrointestinal distress. The drug is currently only approved for sale in Europe, with a date for U.S. availability still uncertain
